Cytori Obtains Celution(R) Approval in Russia; To Launch Product Line for Plastic Surgery and Select Soft Tissue Therapies
Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical…
Cytori Therapeutics (NASDAQ: CYTX) has obtained approval to sell the Celution® 800 System in Russia for various medical…
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of RESTORE-2 trial results in the peer-reviewed Europ…
Cytori (NASDAQ: CYTX) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Puregraft®…
Cytori Therapeutics (NASDAQ: CYTX) today is reporting its third quarter 2011 business update and financial results.…
Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution® System agreement with Apollo Hospitals, one of Asia's la…
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that results from an economic analysis carried out by the UK NH…
Cytori Therapeutics, Inc. (NASDAQ:CYTX) reports that surgeons from North Tees and Hartlepool NHS Foundation Trust have p…
The US Patent and Trademark Office issued a new patent (US Patent No. 7,887,795; direct link to USPTO site - http://bit.…
Cytori Therapeutics, Inc. (NASDAQ:CYTX) has extended the term and modified the focus of its current distribution agreeme…
Cytori Therapeutics (Nasdaq:CYTX) reports second quarter and first half 2010 financial results. Further details, includi…